SSL International plc ('SSL'), the global manufacturer and distributor of premium healthcare products, announces the acquisition of the 'Hibi' branded antiseptic product range ('the Brand'), in all countries of the world except Japan, from AstraZeneca PLC ('AstraZeneca') for a consideration of approximately £46 million in cash. The Brand comprises a number of topical infection control products, principally used in hospitals as medical and surgical skin cleansers for both medical staff and patients. These include the widely recognised Hibiscrub and Hibiclens names, which contain an antimicrobial agent recognised as one of the best topical antiseptics available.

Further small amounts are payable to AstraZeneca if the Brand is introduced to certain geographical markets within two years of the acquisition.

The Brand is sold in over 150 territories, with the largest markets in which SSL has acquired the Brand being North America and Western Europe. The products are currently sourced from a number of AstraZeneca sites around the world, principally in Europe and the USA. After a transitional period, the majority of production will be transferred to SSL's new factory in Peterlee, County Durham.

The assets to be acquired comprise the manufacturing know-how for the Brand, together with certain relevant manufacturing equipment in the UK and USA. The value of tangible net assets to be acquired is approximately £1 million.

Worldwide sales of the Brand in 1999, excluding Japan, were approximately £25 million. Following integration, the margins generated by the Brand are expected to be broadly in line with the existing SSL business. The acquisition is expected to be earnings enhancing in the current year.

The acquisition of the Brand will strengthen SSL's wound management and infection control businesses, particularly in the significant European market. More importantly, it will also complement the rapid launch of Regent surgical gloves into new markets following the investment in increased production capacity already announced.

Commenting on the acquisition, Iain Cater, Chief Executive of SSL, said:

'The Brand is an excellent commercial fit with our existing medical businesses, particularly in the USA, with the significant added benefit of providing a broader European platform from which to expand the sales of our world class Regent surgical gloves.'

'The Brand comprises a well respected product range and its acquisition will also give us the potential for organic growth through the introduction of new wound management and infection control products under the same name.'


For further information, please contact:

SSL International plc
Iain Cater, Chief Executive 01565 624000
Kathryn Lamb, Head of Investor Relations 01565 624000

Square Mile Communications
Louise Robson or Suzanne Walker 0207 601 1000

AstraZeneca UK Limited
Steve Brown, Media 0207 304 5033
Michael Olsson, Investor Relations 0207 304 5087